PTK2 and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma, FAK inhibition with a TKI or shRNA impacted tumor-initiating potential, self-renewal, and metastasis, and improved the response to chemotherapy via CSCs regulation in vitro and in vivo [247].